NLRP3 and peripheral arterial disease: The inflammation expressed in PAD appears to be driven by the inflammasome-IL axis, which would make these patients more sensitive to drugs that modulate IL-1β activity (canakinumab), as well as the NLRP3 inflammasome, which responds to oxidative stress by initiating the cytokine cascade of IL-1β and IL-18 (colchicine).